Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC
© The Author(s). 2016
Received: 7 July 2016
Accepted: 7 November 2016
Published: 20 February 2017
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has become a common treatment approach for disseminated appendiceal neoplasms. Systemic absorption of intraperitoneal chemotherapeutics may lead to drug-induced toxicity, most commonly neutropenia. Mitomycin C has been the most commonly used chemotherapeutic in HIPEC for the past several decades.
Here, we describe a rare pulmonary complication secondary to intraperitoneal administration of mitomycin C.
While rare, intraperitoneal mitomycin C has the potential to cause serious pulmonary toxicity that should be considered with administration. To our knowledge, this report represents only the second case described in the literature.
KeywordsAppendiceal cancer Intraperitoneal chemotherapy Mitomycin C Pulmonary toxicity ARDS
Aggressive surgical approaches to patients with peritoneal carcinomatosis from nongynecologic malignancies have become increasingly common, abrogating some of the historic nihilism associated with treating this difficult patient population . Specifically, over the last three decades, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has emerged as a viable treatment option for selected patients with reasonable morbidity and favorable oncologic outcomes [1, 2].
In patients with disseminated colorectal and appendiceal malignancies undergoing CRS/HIPEC, mitomycin C (MMC) has been the preferred chemotherapeutic agent for decades [3–6]. It is a large molecule with limited systemic absorption, it rapidly penetrates tumor cells, and it is synergistic with hyperthermia [7, 8]. The most common toxicity associated with MMC in HIPEC is neutropenia, which has been shown to occur in up to 39 % of patients [9, 10]. Intravenous MMC is well-known to cause dose-dependent interstitial lung disease, but reports of pulmonary toxicity secondary to intraperitoneal administration are rare [11–13]. Here, we present a case of acute respiratory distress syndrome (ARDS) secondary to MMC administration in a patient recovering from CRS/HIPEC for disseminated appendiceal cancer.
A 38-year-old female with an unremarkable past medical history initially presented to an outside facility with acute-onset low back pain. MRI showed a fluid-filled appendix, and a subsequent CT scan raised concern for acute appendicitis. A laparoscopic appendectomy was performed on the 11th of August 2015 with intraoperative findings of a swollen appendix without any evidence of rupture. Frozen section of the specimen revealed at least low-grade dysplasia with negative margins, and the procedure was terminated at that point. Final pathology revealed invasive adenocarcinoma with evidence of perforation and normal mesoappendix making this a T4Nx tumor. Peritoneal washings revealed tumor cells present.
The patient was then referred to our institution for consideration of CRS/HIPEC. After multidisciplinary tumor board discussion, the patient underwent 3 months of XELOX therapy with plans for interval CRS/HIPEC. In January 2016, the patient underwent laparoscopic right hemicolectomy, omentectomy, and HIPEC. Prior to incision, 1 g of ertapenem was given per routine. No gross disease was appreciated on exploration. The placement of the HIPEC cannulae was performed through the laparoscopic extraction site of the colon and omentum, essentially facilitating a minimally invasive HIPEC. Per institutional practice, HIPEC involved administration of 40 mg MMC with a target intraperitoneal temperature of 41 °C for 90 min. Per institutional protocol, mitomycin C is given at a fixed dose and not dosed by body surface area. Thirty milligrams is administered at time 0 min, and 10 mg administered at time 60 min. Total perfusate is 3 L of normal saline.
During the operation, the patient received 2.2 L of total fluid, primarily lactated Ringer’s solution, over the course of 5 h. No blood products were given, and the patient made 265 mL of urine during the case with an estimated blood loss of 50 mL. The patient’s fluid balance over the next 24 h was essentially even, 2.5 L of saline and 1.8 L of urine output recorded. No blood products were given postoperatively either.
At no point during the postoperative course was there ever any evidence of abdominal sepsis to explain the pulmonary findings. Throughout her postoperative course, her abdomen remained appropriately soft; she had an early return of bowel function, with no clinical evidence of peritonitis. Furthermore, an abdominal CT scan done at the onset of respiratory insufficiency on postoperative day 2 showed normal postsurgical changes, but no fluid collection or other evidence of anastomotic leak, making an abdominal source for her pulmonary toxicity unlikely.
The patient experienced mild neutropenia 5 days following the onset of respiratory distress, which resolved within a few days. Prior to her operation, the patient had a white blood cell count of 3.9 × 109 cells/L, which increased within the normal range to 7.9 × 109 at the onset of respiratory insufficiency. Her white blood cell count then progressively decreased to a mild neutropenia, reaching 2.6 × 109 by postoperative day 7. At the time of her discharge her neutropenia had resolved, with a count of 8.0 × 109.
At the patient’s most recent follow-up appointment, over 1 month postoperatively, she reported no shortness of breath or chest pain, with an oxygen saturation of 99 % on room air with a respiratory rate of 16. Overall, she is doing well from a respiratory standpoint. She is scheduled to restart systemic chemotherapy.
Cytoreductive surgery in combination with HIPEC is a well-accepted and increasingly utilized treatment strategy for patients with disseminated appendiceal malignancies. MMC is the most frequently used chemotherapeutic agent for this approach, in part due to its high molecular weight that allows for limited systemic penetration . Unlike conventional systemic chemotherapy for appendiceal cancer, which has limited access to the peritoneum, MMC HIPEC allows for high local doses targeted at residual micrometastatic peritoneal disease [7, 14]. The hyperthermia used in HIPEC synergizes with the antitumor effects of intraperitoneal chemotherapy by increasing cytotoxicity as well as the depth of penetration by the drug .
Although this strategy has favorable oncologic outcomes compared to systemic chemotherapy alone, CRS/HIPEC carries potential for significant adverse effects. Morbidity following this treatment is most commonly related to cytoreductive surgery; yet, there remains a risk for MMC-related toxicity . The most frequent side effect from peritoneal MMC is neutropenia, for which female sex and MMC dose per body surface area have been implicated as risk factors . The patient presented in this case, although she had a significant drop in white blood cell count resulting in a Grade 2 leukocyte toxicity (from 7.2 × 109 to 2.5 × 109), did not experience neutropenia (ANC 2.2 × 109) . Of note, she also had a significant drop in her hemoglobin to a Grade 3 anemia (10.4 to 7.3 g/dL) without significant blood loss .
More notable and unique in this case was the onset of respiratory symptoms after treatment with MMC. This patient was ultimately diagnosed with ARDS beginning 2 days post-therapy due to a constellation of factors that include acute-onset respiratory insufficiency with an FiO2/paO2 of 250, bilateral pulmonary infiltrates on imaging, and lack of cardiogenic pathology. The presence of a degree of myelosuppression in this patient, as evidenced by the drop in her ANC and hematocrit postoperatively, confirms an element of systemic absorption of MMC, which supports the diagnosis of MMC toxicity-induced ARDS. Given the negative infectious workup, a noninfectious cause for ARDS in this patient was strongly favored. The strong temporal relationship with administration of intraperitoneal mitomycin C and development of pulmonary toxicity also favors drug toxicity as the inciting cause for ARDS. Given the well-established relationship between systemic mitomycin C and development of interstitial pneumonitis, the pulmonary and critical care teams strongly favored this diagnosis. However, given the patient’s relatively rapid recovery, no lung biopsy was performed and empiric steroid therapy was never instituted.
A recent study on the neutropenic effects of MMC HIPEC resulted in a standardized, weight-based algorithm dosing system adjusted for the presence of prior systemic chemotherapy to minimize neutropenia . This patient received a dose of MMC HIPEC consistent with this algorithm. While she did not develop neutropenia, we believe that the development of ARDS in addition to an evidence of myelosuppression is both attributable to intraperitoneal administration of MMC. Unique to this patient is her BMI being <20 (19.3) and her body surface area being only 1.61 m2. Side effects of MMC HIPEC are reported to happen at a median BMI of 25.5 (range 19–36.2) and BSA of 1.77 (range 1.39–2.36) .
The first cases of interstitial pneumonitis during treatment with intravenous MMC were reported in 1978 . Following this publication, pulmonary toxicity continued to be reported as a rare but well-known side effect of MMC, with occurrence rates of 5 to 12 % . The first prospective study on the relationship between intravenous MMC and pulmonary toxicity concluded that this toxicity is a dose-dependent side effect of MMC that should be considered only when patients receive over a 20 mg/m2 cumulative dose . This model was supported by later pharmacological evidence that there is a direct relationship between body surface area and MMC plasma clearance, as well as between plasma exposure and hematological toxicity . Recommendations of this study were to use a dose of 25 mg/m2, divided into three portions of 50 % at the beginning of treatment, 25 % after 30 min, and 25 % after another 30 min, in order to limit the incidence of leukopenic side effects to 10 %.
Despite the established relationship between intravenous MMC and interstitial pneumonitis, large studies of MMC HIPEC-induced pulmonary toxicity have yet to be reported in the literature. A 2008 report outlined the first published case of HIPEC MMC-induced interstitial pneumonitis in a patient who received 30.8 mg/m2 HIPEC MMC within the standard treatment dosing parameters . This case similarly demonstrated systemic penetration of MMC despite dosing according to established guidelines. Unlike the patient presented here, however, the previous case describes a case of interstitial pneumonitis 37 days following therapy, requiring steroids but without need for intubation. Both accounts draw attention to the potential for respiratory toxicity associated with HIPEC MMC.
It remains unclear what, if any, underlying factors may have predisposed these patients to acquire respiratory insufficiency, but the existence of such factors could/may help providers better predict which patients are vulnerable to these side effects. Although rare, it is clear that oncologists must be aware of the potential for pulmonary toxicity of MMC, which we have seen possible with either intravenous or intraperitoneal administration. These events should be monitored for and treated aggressively, and further cases must continue to be reported to bring insight to the mechanisms that underlie this process, which patients may be at increased risk, and how dosing of HIPEC MMC might be altered to avoid further complications.
Absolute neutrophil count
Acute respiratory distress syndrome
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy
Availability of data and materials
Data is available in our institution’s secure storage hard drive.
MA contributed to the manuscript preparation and literature review. GK and DGB contributed to the manuscript preparation and are the operating surgeons. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Lambert LA. Looking up: recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin. 2015;65(4):284–98.View ArticlePubMedGoogle Scholar
- Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221(2):124–32.View ArticlePubMedPubMed CentralGoogle Scholar
- Gonzalez-Moreno S. Peritoneal Surface Oncology: a progress report. Eur J Surg Oncol. 2006;32(6):593–6.View ArticlePubMedGoogle Scholar
- Stephens AD, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6(8):790–6.View ArticlePubMedGoogle Scholar
- Stewart JH, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13(5):624–34.View ArticlePubMedGoogle Scholar
- Yan TD, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14(10):2702–13.View ArticlePubMedGoogle Scholar
- Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am. 2003;12(3):673–88.View ArticlePubMedGoogle Scholar
- Kuzuya T, et al. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol. 1994;46(8):685–9.View ArticlePubMedGoogle Scholar
- Lambert LA, et al. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol. 2009;16(8):2181–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Kemmel V, et al. Mitomycin C pharmacokinetics as predictor of severe neutropenia in hyperthermic intraperitoneal therapy. Ann Surg Oncol. 2015;22 Suppl 3:873–9.View ArticleGoogle Scholar
- Twohig KJ, Matthay RA. Pulmonary effects of cytotoxic agents other than bleomycin. Clin Chest Med. 1990;11(1):31–54.PubMedGoogle Scholar
- Saif MW, Dai T. Mitomycin-induced interstitial pneumonitis in a patient with BRCA2 associated metastatic pancreatic carcinoma. JOP. 2010;11(3):277–9.PubMedGoogle Scholar
- Gonzalez-Moreno S, Lambert LA, Mansfield PF. Interstitial pneumonitis: an exceptional toxicity of hyperthermic intraperitoneal mitomycin C. Eur J Surg Oncol. 2008;34(4):482–4.View ArticlePubMedGoogle Scholar
- van Ruth S, Verwaal VJ, Zoetmulder FA. Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am. 2003;12(3):771–80.View ArticlePubMedGoogle Scholar
- Institute NC. Common terminology criteria for adverse events v4.0. NCI, NIH, DHHS.
- Orwoll ES, Kiessling PJ, Patterson JR. Interstitial pneumonia from mitomycin. Ann Intern Med. 1978;89(3):352–5.View ArticlePubMedGoogle Scholar
- Thompson CC, et al. Postoperative pulmonary toxicity associated with mitomycin-C therapy. South Med J. 1992;85(12):1257–9.View ArticlePubMedGoogle Scholar
- Verweij J, et al. Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer. 1987;60(4):756–61.View ArticlePubMedGoogle Scholar